Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|June 12, 2026 (Updated: June 10, 2026)

The BioPharm Brief: Hormones, Metabolism, Momentum

New clinical data highlight advances in endocrine, metabolic, and rare disease drug development, with positive updates from MBX Biosciences, Gan & Lee Pharmaceuticals, and Novartis.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Today, we're looking at new clinical data across three therapeutic areas, chronic hypoparathyroidism, metabolic disease, and facioscapulohumeral muscular dystrophy, or FSHD. The updates underscore continued efforts to develop longer-acting therapies and disease-modifying treatments for conditions with significant unmet need.

First, MBX Biosciences reported one-year data for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for chronic hypoparathyroidism. In the ongoing open-label extension study, 57% of evaluable patients maintained responder status at one year, while serum calcium levels remained within the normal range and kidney function measures improved. The company says the findings support advancement into a Phase 3 trial, which remains on track to begin later this year.

Next, Gan & Lee Pharmaceuticals announced positive results from multiple studies evaluating insulin ludefen and the GLP-1 receptor agonist bofanglutide. Across Type 2 diabetes, obesity, and metabolic dysfunction-associated steatotic liver disease, the candidates met key clinical endpoints, including improvements in glycemic control, weight reduction, and liver fat content. The results add to growing competition in the rapidly evolving metabolic disease market.

Finally, Novartis reported positive biomarker data from the Phase 1/2 FORTITUDE study of delpacibart braxlosiran, an investigational antibody oligonucleotide conjugate for FSHD. The therapy met its primary and key secondary endpoints, demonstrating reductions in biomarkers associated with DUX4 activity and muscle damage. Novartis plans to discuss the data with regulators while continuing enrollment in its Phase 3 study.

Those are today's highlights shaping the future of endocrine, metabolic, and neuromuscular medicine.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

  • MBX's canvuparatide delivered sustained one-year results in chronic hypoparathyroidism and remains on track for phase 3.
  • Gan & Lee reported positive metabolic disease data across diabetes, obesity, and liver disease programs.
  • Novartis advanced its FSHD program with positive biomarker results supporting ongoing Phase 3 development.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more